This article only represents the author's own views.
By now, many people have heard of Sinovac Biotech Ltd. (SVA.US), the maker of one of the three globally accepted Covid-19 vaccines developed in China. But few likely realize the company is listed on the Nasdaq, providing an interesting investment opportunity, as its revenue soars on strong sales of its CoronaVac vaccine.
There’s a good reason many people may not realize Sinovac is publicly traded in the U.S.
您已閱讀7%（462字），剩餘93%（5753字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。